Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Blueberries Medical Corp. (BBRRF)
USD0.01
+0.00 (+0.00%)
CO OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
Calle 93 # 15 - 51 Oficina 406
Bogotá, CO
Bogotá, CO
CEO
Facundo Garreton
Website
blueberriesmed.com
IPO
2019-02-08
ISIN CA09609Y1016
Also trades on
Canadian Securities Exchange · BBM.CN (CAD)
Other OTC · BBRRF (USD)
Description
Blueberries Medical Corp. conducts comprehensive operations in Colombia, covering the entire process of medicinal cannabis and its derivative products—from their initial cultivation and development to final production and distribution. The company specializes in providing pharmaceutical-grade cannabis oil extracts along with other associated therapeutic products. Its corporate headquarters are situated in Bogotá, Colombia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.01
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
30.6K
Beta
2.64
Float Shares
68.03M
Free Float %
13.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -13.28% | +7.77% | +8.29% | +2.78% | +8.82% | -3.48% | +7.77% | +5.71% | -86.13% | -93.83% | -97.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.01
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-53.93
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-33.8% Q1'26: -22.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-17.2% Q1'26: +115.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-439.4% Q1'26: -32.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-441.6% Q1'26: -368.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-456.7% Q1'26: -857.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+18.5% Q1'26: +22.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.01× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
|---|---|---|---|---|
| Revenue |
66.0K
est: 5.99M (-98.9%)
|
138.7K
est: 14.64M (-99.1%)
|
235.4K
est: 26.37M (-99.1%)
|
288.3K
est: 53.16M (-99.5%)
|
| EBITDA |
-3.57M
est: -5.99M (+40.4%)
|
-1.08M
est: -14.64M (+92.6%)
|
-1.35M
est: -26.37M (+94.9%)
|
-1.22M
est: -53.16M (+97.7%)
|
| EBIT |
-4.12M
est: -5.99M (+31.2%)
|
-1.79M
est: -14.64M (+87.8%)
|
-1.64M
est: -26.37M (+93.8%)
|
-1.37M
est: -53.16M (+97.4%)
|
| Net Income |
-4.94M
est: -4.00M (-23.5%)
|
-5.15M
|
-1.47M
est: 7.91M (-118.6%)
|
-1.64M
est: 19.95M (-108.2%)
|
| SGA |
2.48M
est: 64.16M (-96.1%)
|
579.4K
est: 156.71M (-99.6%)
|
1.23M
est: 282.22M (-99.6%)
|
1.31M
est: 569.08M (-99.8%)
|
| EPS |
-0.04
est: -0.01 (-298.1%)
|
-0.03
|
-0.01
est: 0.02 (-143.9%)
|
-0.01
est: 0.05 (-115.0%)
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-2.77M
OE per share TTM
-0.01
Owner's Yield
-54.29%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
981.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-2.8K
Shares Outstanding
495.09M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thomas Rodriguez | Chief Financial Officer | 89.3K | male |
| Facundo Garreton | Executive Chairman & Chief Executive Officer | 88.5K | male |
| Gustavo Gutiérrez | Country Manager | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BBRRF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
